Multifractionated dosing for chemotherapy with flexible cytokine use: Strategy for optimizing the therapeutic index

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 25, Issue 1, 2002, Pages 101-102

  Lokich, Jacob ^a  

^a Cancer Center of Boston   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYTOKINE; GEMCITABINE; IRINOTECAN; NAVELBINE; PACLITAXEL; TAXANE DERIVATIVE;

ARTICLE; CANCER; CANCER CHEMOTHERAPY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; HUMAN; PRACTICE GUIDELINE; PROPHYLAXIS;

ANTINEOPLASTIC AGENTS; CYTOKINES; HUMANS;

EID: 0036159914     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-200202000-00022     Document Type: Article

References (6)

1. Multifractionated dosing for cancer chemotherapy: A novel schedule and a work in progress
2. Single-dose granulocyte colony-stimulating factor concomitant with multifractionated dose chemotherapy: A strategy for maintaining dose intensity
3. Combined paclitaxel, cisplatin, etoposide in previously untreated esophageal and gastroesophageal cancers
4. Paclitaxel, cisplatin, etoposide combination chemotherapy: A comparison of dose intensity in two multifractionated dose schemas
5. The multifractionated, twiceweekly dose schedule for a three-drug chemotherapy regimen. A phase I-II study of paclitaxel, cisplatin and vinorelbine
6. Dose intensity for bolus versus infusion chemotherapy administration: Review of the literature for 27 antineoplastic agents